原发性肝癌与甲胎蛋白研究进展

辛永宁; 宣世英

原发性肝癌与甲胎蛋白研究进展

详细信息

中图分类号: R735.7
计量
- 文章访问数: 1924
- HTML全文浏览量: 3
- PDF下载量: 926
- 被引次数: 0
出版历程
- 出版日期: 2007-02-20

摘要

HTML全文

参考文献(25)

[1]Semeniuk DJ, Boismenu R, Tam J, et al.Evidence that immuno-suppression is an intrinsic property of the alpha-fetoprotein molecule[J].Adv Exp Med Biol, 1995, 383∶255-69.

[2]Meng WS, Butterfield LH, Ribas A, et al.Fine specificity analysisof an HLA-A2.1-restricted immunodominant T cell epitope de-rived from human alpha-fetoprotein[J].Mol Immunol, 2000, 37 (16) ∶943-950.

[3]Mizejewski GJ.Alpha-fetoprotein structure and function:relevanceto isoforms, epitopes, and conformational variants[J].Exp Biol Med (Maywood) , 2001, 226 (5) ∶377-408.

[4]Gillespie JR, Uversky VN.Structure and function of alpha-fetopro-tein:a biophysical overview[J].Biochim Biophys Acta, 2000, 1480 (1-2) ∶41-56.

[5]Gotsman I, Israeli D, Alper R, et al.Induction of immune tolerancetoward tumor-associated-antigens enables growth of human hepato-ma in mice[J].Int J Cancer, 2002, 97 (1) ∶52-57.

[6]Dudich E, Semenkova L, Gorbatova E.Growth-regulative activityof human alpha-fetoprotein for different types of tumor and normalcells[J].Tumour Biol, 1998, 19 (1) ∶30-40.

[7]Wang XW, Xie H.Alpha-fetoprotein enhances the proliferation ofhuman hepatoma cells in vitro[J].Life Sci, 1999, 64 (1) ∶17-23.

[8]Wang XW, Xu B.Stimulation of tumor-cell growth by alpha-feto-protein[J].Int J Cancer, 1998, 75 (4) ∶596-599.

[9]Li MS, Li PF, He SP, et al.The promoting molecular mechanism ofalpha-fetoprotein on the growth of human hepatoma Bel7402 cellline[J].World J Gastroenterol, 2002, 8 (3) ∶469-475.

[10]Semenkova LN, Dudich EI, Dudich IV.Induction of apoptosis inhuman hepatoma cells by alpha-fetoprotein[J].Tumour Biol, 1997, 18 (5) ∶261-273.

[11]Vollmer CMJr, Eilber FC, Butterfield LH, et al.Alpha-fetopro-tein-specific genetic immunotherapy for hepatocellular carcinoma[J].Cancer Res, 1999, 59 (13) ∶3064-3067.

[12]Nagao M, Nakajima Y, Kanehiro H, et al.The impact of interferongamma receptor expression on the mechanism of escape from host im-mune surveillance in hepatocellular carcinoma[J].Hepatology, 2000, 32 (3) ∶491-500.

[13] Ozoren N, E1-Deiry WS.Cell surface Death Receptor signaling innormal and cancer cells[J].Semin Cancer Biol, 2003, 13 (2) ∶135-147.

[14]Hahne M, Rimoldi D, Schroter M, et al.Melanoma cell expressionof Fas (Apo-1/CD95) ligand:implications for tumor immune escape[J].Science, 1996, 274 (5291) ∶1363-6.

[15]Patel T.Immune escape in hepatocellular cancer:is a good offensethe best defense[J].Hepatology, 1999, 30 (2) ∶576-578.

[16]Smyth MJ, Takeda K, Hayakawa Y.Nature's TRAIL-on a path tocancer immunotherapy[J].Immunity, 2003, 18 (1) ∶1-6.

[17]Seki N, Hayakawa Y, Brooks AD, et al.Tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis is an impor-tant endogenous mechanism for resistance to liver metastases in mu-rine renal cancer[J].Cancer Res, 2003, 63 (1) ∶207-213.

[18]Yamashita Y, Shimada M, Tanaka S, et al.Electroporation-me-diated tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) /Apo2L gene therapy for hepatocellular carcinoma[J].Hum Gene Ther, 2002, 13 (2) ∶275-286.

[19]Nagata S.Fas ligand-induced apoptosis[J].Annu Rev Genet, 1999, 33∶29-55.

[20]Takakuwa T, Dong Z, Nakatsuka S, et al.Frequent mutations ofFas gene in nasal NK/T cell lymphoma[J].Oncogene, 2002, 21 (30) ∶4702-4705.

[21]Nagao M, Nakajima Y, Hisanaga M, et al.The alteration of Fas re-ceptor and ligand system in hepatocellular carcinomas:how do hepa-toma cells escape from the host immune surveillance in vivo?[J].Hepatology, 1999, 30 (2) ∶413-421.

[22]Dudich E, Semenkova L, Dudich I, et al.alpha-fetoprotein cau-ses apoptosis in tumor cells via a pathway independent of CD95, TN-FR1 and TNFR2 through activation of caspase-3-like proteases[J].Eur J Biochem, 1999, 266 (3) ∶750-761.

[23]Li MS, Li PF, Yang FY, et al.The intracellular mechanism of al-pha-fetoprotein promoting the proliferation of NIH 3T3 cells[J].Cell Res, 2002, 12 (2) ∶151-156.

[24]常家聪, 刘弋, 宋海屏, 等.原发性肝癌组织中HBsAg、AFP的研究[J].中国普通外科杂志, 1996, 5 (1) ∶11-12.

[25]邓洪, 周元平, 徐启桓, 等.HBsAg阳性与阴性肝癌患者治疗前后的临床特点分析[J].癌症, 2000, 19 (11) ∶1033-1035.

施引文献

资源附件(0)

访问统计